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Abstract
Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced ‘castrate-resistant’ disease
(CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, hormone-responsive and
-resistant PC cells expressing a luciferase-based AR reporter were transfected with a miR inhibitor library; 78 inhibitors
significantly altered AR activity. Upon validation, miR-346, miR-361-3p and miR-197 inhibitors markedly reduced AR
transcriptional activity, mRNA and protein levels, increased apoptosis, reduced proliferation, repressed EMT, and inhibited
PC migration and invasion, demonstrating additive effects with AR inhibition. Corresponding miRs increased AR activity
through a novel and anti-dogmatic mechanism of direct association with AR 6.9 kb 3′UTR and transcript stabilisation. In
addition, miR-346 and miR-361-3p modulation altered levels of constitutively active AR variants, and inhibited variant-
driven PC cell proliferation, so may contribute to persistent AR signalling in CRPC in the absence of circulating androgens.
Pathway analysis of AGO-PAR-CLIP-identified miR targets revealed roles in DNA replication and repair, cell cycle, signal
transduction and immune function. Silencing these targets, including tumour suppressors ARHGDIA and TAGLN2,
phenocopied miR effects, demonstrating physiological relevance. MiR-346 additionally upregulated the oncogene,
YWHAZ, which correlated with grade, biochemical relapse and metastasis in patients. These AR-modulatory miRs and
targets correlated with AR activity in patient biopsies, and were elevated in response to long-term enzalutamide treatment of
patient-derived CRPC xenografts. In summary, we identified miRs that modulate AR activity in PC and CRPC, via novel
mechanisms, and may represent novel PC therapeutic targets.
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Introduction
Prostate cancer (PC) is the most prevalent malignancy in
Western males [1]. Initially, growth of prostate tumours is
dependent on circulating androgens activating the androgen
receptor (AR) [2]. Targets of this ligand-activated tran-
scription factor include effectors of cell cycle progression
and proliferation, hence androgen deprivation remains a
first-line approach for treatment of metastatic PC. However,
relapse almost invariably occurs as tumours progress to
refractory and largely lethal ‘castrate-resistant’ status
(CRPC). Despite the lack of requirement of CRPC tumours
for circulating androgens, it is widely accepted that AR
signalling is still driving their growth. Mechanisms of per-
sistent AR activity include increased sensitivity to remain-
ing androgens (e.g. adrenal androgens), ligand promiscuity,
AR gene amplification or mutation, altered AR mRNA
splicing leading to constitutively active forms, aberrant
expression of AR coregulators and intra-tumoural androgen
synthesis [3]. Thus compounds reducing AR levels and/or
activity are likely to be effective in CRPC, for which
treatment options are severely limited. Hence, Abiraterone
(Abi – a CYP17A inhibitor with AR-inhibitory activity) and
Enzalutamide (Enza – an anti-androgen) are recommended
for CRPC treatment [4]. Unfortunately, acquired resistance
to drugs targeting the AR ligand binding domain (LBD) is
an increasing clinical problem, so novel therapeutics that
repress AR through non-LBD-mediated mechanisms will be
important additions to the CRPC treatment repertoire.
MiRs are 20–25 bp non-coding RNAs that regulate gene
expression through interaction with complementary binding
sites in target mRNAs, most commonly in 3′ untranslated
regions (3′UTRs). Mammalian miRs are transcribed by
RNA polymerase II, generating a primary miR (pri-miR)
transcript that undergoes several processing steps to the
mature miR by way of a precursor stage (pre-miR), usually
requiring the nuclear Drosha- and DiGeorge Critical Region
8 (DGCR8)-containing Microprocessor (MP) complex, the
RNase III enzyme, Dicer, and the RNA-induced silencing
complex (RISC) [5]. Then, mature miR associates with
Argonaute 2 (AGO2) of the RISC and guides the complex
to complementary sequences within the 3′-UTR of target
mRNAs, usually resulting in translational repression and/or
transcript degradation. There is a wealth of evidence for the
importance of miRs, several of which can function as
tumour-promoting oncogenes (or “oncomiRs”) and also
tumour suppressors in hormone-regulated cancers [6–9], in
PC. Androgen regulation of numerous miRs has been
demonstrated, also miR expression profiles are altered
during PC progression, with dysregulation in CRPC com-
pared to androgen-dependent tumours [7, 10–14]. Their
roles in PC likely include altering androgen signalling via
targeting of AR itself, AR target genes or AR coregulatory
proteins, opening up multiple avenues for future therapeutic
development. However, surprisingly little is known con-
cerning the repertoire of miRs that modulate AR activity.
Previously, Östling et al. [15] used a pre-miR library to
perform gain-of-function screening for AR-modulatory
miRs in PC cell lines. Thirteen miRs were validated as
significantly reducing AR 3′-UTR activity: miR-135b, miR-
185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-
3p, miR-421, miR-449a, miR-449b, miR-634, miR-654-5p
and miR-9 [15]. AR targeting by miR-185 was also shown
by Qu et al. [16], who demonstrated that miR-185 sig-
nificantly reduces AR protein (but not mRNA) in LNCaP
cells, and decreases LNCaP proliferation and xenograft
tumourigenicity. AR targeting by miR-34a was previously
shown by Kashat et al. [17], in C4-2B and CWR22Rv-1
cells. Other miRs also target AR directly: Hagman et al.
[18] demonstrated ectopic miR-205 overexpression to sig-
nificantly decrease AR protein levels and 3′-UTR activity in
VCaP cells, although this was not recapitulated in LNCaP
cells. In addition, miR-205 levels were low in all but one PC
cell line, so the physiological relevance in PC is in question.
Similarly, AR mRNA and protein levels, AR transcriptional
activity and AR 3′UTR reporter activity were all decreased
following ectopic expression of miR-488-5p in androgen-
dependent and -independent PC cells [19]. In 2016, com-
prehensive, complementary functional screening for AR
activity-regulating miRs, using a library of miR mimics [13]
highlighted miR-30 family members as directly inhibiting
AR activity through 3′UTR association; it also showed
them to reduce PCa cell proliferation and inversely correlate
with mRNA levels of the AR target gene PSA in clinical
samples. This work also corroborated miR-488-5p as an
AR-targeting miR. Our work complements the above miR
mimic screening approach through use of a miR inhibitor
library in androgen-dependent and -independent PC cell
lines. A miR inhibitor library was selected since, unlike
miR mimics, inhibitors do not deplete cells of endogenous
miR processing or effector complexes (such as RISC),
which could lead to off-target or non-specific effects.
Indirect regulation of AR by miRs is also evident in PC
cells. For example, the tumour-suppressive miR, let-7c,
reduces AR activity and PC cell growth by repressing the
oncogenes Ras and c-Myc [20, 21], as Myc is required for
AR transcriptional activity [22]. Let-7c expression is fre-
quently reduced, or its gene deleted, in cancer [12, 23].
Similarly, miR-331-3p reduces AR activity in several PC
cell lines by targeting the oncogene ERBB2 [24], which can
activate transcription of AR target genes in the absence of
androgens [25]. Tumour-suppressive, AR-inhibitory miRs
such as these could be exploited as therapeutics for PC,
alone or in combination with anti-androgens.
The above findings demonstrate the importance of miRs
in regulation of AR activity, both directly and indirectly.
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However, much remains to be learnt surrounding mutual
regulation of miRs and AR. Thus we sought a miRnome-
wide approach to identify AR-modulatory miRs that may
represent novel therapeutics, drug targets or biomarkers in
PC. We used LNCaP and C42 cell lines to model androgen-
dependent and CRPC stages of the disease respectively,
with expression of an integrated luciferase-based AR
activity reporter as an easily-assayable end-point [26]. To
perform a non-biased screen with high coverage of the
potential miR repertoire, we transfected these with a library
comprising LNA-modified antisense inhibitors against 983
human miRs. Importantly, this strategy identified not only
miRs that target AR directly, but also those that modulate
AR activity indirectly by targeting AR cofactors, chaper-
ones, pioneer factors and effector proteins.
Results
Identification and validation of AR-modulatory MiRs
In order to identify miRs that modulate AR activity in
androgen-dependent and -independent PC, LNCaP and C42
cells stably expressing a luciferase-based AR activity
reporter [26] (Fig. 1a) were transfected with a library of 983
miR inhibitors. Luciferase assays were performed and B
Score calculated. Using a stringent B score of ±6, 78 miR
inhibitors were found to significantly modulate AR reporter
activity (B Score ≥ 6 in at least one PC cell line), 63%
negatively and 37% positively. B score correlation between
LNCaP and C42 cells, and top 30 hits are shown (Fig. 1c,
Table S2, respectively). Eight miR inhibitors significantly
altered AR activity in the same direction in both LNCaP and
C42 cells (B Score ≥ 6, Fig. 1b, Table S2), while no inhi-
bitors significantly modulated AR activity in opposite
directions in the two cell lines at B Score ≥6. MiR-346,
-361-3p and -197-3p were selected from top ten ‘hits’ due to
their high B scores and confirmed expression in cell lines
(Ct < 35 in LNCaP cells). To confirm the ability of these
miRs to regulate AR activity in androgen-dependent and
-independent settings, inhibitors or mimics were transfected
into LNCaP/ARE and C42/ARE and luciferase assays per-
formed. Figure S1a confirms significantly increased miR
levels in C42 cells transfected with miR mimics. MiR-346
inhibitor significantly reduced AR activity by up to 90% in
a dose-dependent manner in LNCaP/ARE and C42/ARE
cells (Fig. 1di, ii). AR activity was not altered following
transfection of a non-targeting inhibitor (Fig. S1b). Con-
versely, miR-346 mimic increased AR activity by 70% in
LNCaP/ARE cells, an effect not significant in C42/ARE
cells (Fig. 1diii, iv). Similarly, miR-361-3p inhibitor sig-
nificantly repressed AR activity by up to 80% in both cell
lines (Fig. 1ei, ii), while miR-361-3p mimic significantly
increased AR activity by up to fivefold (Fig. 1eiii, iv).
Comparable data were obtained for miR-197 inhibitor,
which decreased AR activity by up to 50% (Fig. 1fi, ii),
although miR-197 mimic did not significantly increase AR
activity in either cell line (Fig. 1fiii, iv). Further, miR
mimics are able to rescue effects of miR inhibitors, ver-
ifying that these are not off-target effects (Fig. 2a, c).
Modulation of MiR-346, -361-3p and -197 alters AR
wild-type and variant mRNA, protein and 3′UTR
activity
Given that modulating miR-346, -361-3p and -197 sig-
nificantly altered AR activity, we hypothesised that this may
be due to changes in AR mRNA or protein levels. Thus,
C42 and LNCaP cells were transfected with inhibitor and/or
mimic and AR mRNA and protein levels assessed 24 h
post-transfection. Non-targeting miR inhibitors and mimics
did not significantly modulate AR activity in either cell line
(Fig S1b). It was shown that inhibition of each miR under
investigation significantly reduced AR mRNA levels by up
to 70% (Fig. 2a, Fig. S1c), and that addition of mimic in the
presence of inhibitor could rescue AR mRNA loss in a
dose-dependent manner, an effect significant for miR-346
(Fig. 2ai). Further, inhibition of miR-346, -361-3p and
-197 significantly reduced AR protein levels in a dose-
dependent manner, also rescued through addition of miR
mimic (Fig. 2b, Fig. S1d–h). Similar effects were observed
in LNCaP cells (Fig. S1f, g, h).
To examine effects of miR manipulation on AR tran-
scriptional output, we assessed levels of the endogenous AR
target genes, PSA, TMPRSS2 and DRG1 in both LNCaP and
C42 cells. Inhibition of miR-346, -361-3p or -197 was
found to significantly reduce PSA mRNA levels by up to
75% in LNCaP cells (Fig. 2c). Loss of PSA mRNA was
rescued through addition of miR-346 mimic, and miR-346
mimic alone was found to significantly increase PSA
mRNA levels compared to mock-transfected cells (Fig. 2ci).
Similar results were obtained for other AR target genes in
both LNCaP and C42 (Fig. S2a–d). To assess whether
upregulation of AR activity and protein levels occurs
through direct miR activity at the AR 3′UTR, we analysed
AR 3′UTR for miR-346, -361-3p and -197 seed region
complementarity. Although algorithm-based miR binding
prediction tools such as microrna.org and DIANAmicroT
predict miR associations with an AR 3′UTR of 436 nt and
c. 3 kb, respectively, a number of studies have identified AR
3′UTR lengths of between 6.6 and 6.9 kb in PC cells [27]
resulting from alternative polyadenylation [15], meaning
that large numbers of biologically important potential miR:
AR 3′UTR interactions may be missed during bioinformatic
analysis. Thus, 6.8 Kb AR 3′UTR sequence (from
NM_000044 was examined for miR binding sites). Two
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miR-361-3p binding sites (complete seed complementarity)
were identified within the proximal region of AR 6.8 kb 3′
UTR at nucleotides 407–412 and 787–793 (although only
the first is within the 436 nt short AR 3′UTR), with a further
two sites identified distally at 5772–5777 and 6070–6075
(Fig. 2di). MiR-346 binding sites were identified at
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3185–3190 and 6283–6288, and miR-197 binding sites at
3043–3048 and 4308–4313, none within the standard short
AR 3′UTR. All sites were relatively poorly conserved
across species, with the exception of the miR-197 site at
4308–4313, which was completely conserved across almost
all mammals (Fig. S3).
To examine the functionality of these regions of seed
complementarity, we performed luciferase assays in
HEK293T cells using reporter vectors containing seven
overlapping regions of AR 6.8 kb 3′UTR downstream of a
luciferase gene (Fig. 2d, e) [13]. Effects of miR-361-3p on
the 787–793 region were not assessed as the complete
sequence of this region lies between sequences found in AR
3′UTR reporters #1 and #2. In contrast to the predominant
repressive effects usually observed for miRs at 3′UTRs, we
found that miR-361-3p increased activity of AR 3′UTR
reporters #1, #6 and #7 (all of which contain putative miR-
361-3p binding sites) (Fig. 2dii, v, vi), while addition of the
corresponding inhibitor significantly reduced AR 3′UTR
activity (Fig. 2di, iv, v). Interestingly, miR-346 modulation
had no effect on activity of AR 3′UTR reporter #4, despite
this region containing a miR-346 7mer1a site (Fig. 2diii).
Likewise, AR 3′UTR reporter #4 activity was only mini-
mally increased by addition of miR-197 (although sig-
nificantly decreased by miR-197 inhibitor), despite
containing a miR-197 6mer site (Fig. 2diii). MiR-197
increased luciferase activity of AR 3′UTR reporter #5,
which was partially rescued by addition of miR-197 inhi-
bitors (Fig. 2div). Finally, miR-346 slightly increased
activity of AR 3′UTR reporter #7, an effect abrogated
through addition of inhibitor (Fig. 2dvi). Addition of miR-
346 to HEK293T cells transfected with AR 3′UTR reporter
2 or 3 (no putative miR-346 binding sites) did not alter
luciferase activity, as expected (Fig. S2E). Further, above
effects of miR-361-3p addition were replicated in C42 cells
(Fig. 2e). The observation that miR-361-3p produces a
greater increase in region 1 and 7 AR 3′UTR activity in C42
cells (Fig. 2ei, iii) as compared to HEK293T cells (Fig. 2dii,
vi) may reflect the increased importance of this mode of AR
regulation in AR-requiring PC cells as compared to non-
cancer lines.
To confirm specificity of interaction of AR-modulatory
miRs with identified seed region complementary sequences
(Fig. 2d), key residues within miR binding sites were
mutated in those AR 3′UTR reporters that demonstrated
altered activity upon miR transfection. MiR-361-3p induc-
tion of AR 3′UTR activity was significantly reduced upon
mutation of miR-361-3p binding sites of reporters #1, #6
and #7 in C42 cells (Fig. 2e), with similar results observed
in HEK293T cells (Fig. S2Fiii-v). Interestingly, luciferase
activity of neither wild-type nor miR-197 binding site-
mutant AR 3′UTR reporter #5 was altered upon miR-197
transfection at the 24 h timepoint (Fig. S2Fi). Mutation of
miR-346 binding site in AR 3′UTR reporter #7 reduced
miR-346-induced increase in activity of the wild-type vec-
tor, albeit non-significantly (Fig. S2Fii). In order to identify
physiological association of AR-modulatory miRs with AR
transcript, we performed AGO/biotin-miR RNA-IP,
whereby biotin-labelled miR mimic-transfected cells are
subjected to a two-step IP with anti-AGO2 antibody, fol-
lowed by streptavidin IP, RNA extraction and qRT-PCR.
Minimal enrichment of AR transcript was identified in
presence of miR-197 or -346, and AR enrichment levels
were similar to those observed for the abundant house-
keeping gene GAPDH, which lacks predicted miR-346 and
-197 binding sites (Fig. 2f). In agreement with this obser-
vation, AGO-PAR-CLIP did not identify AR as a target of
either miR-346 or -197(36), although this may be due to use
of standard AR 3′UTR sequence length upon read align-
ment during data processing. Nevertheless, we hypothesised
that miR:AR interaction may be very transient, and thus
undetectable by RNA-IP methodologies. Alternatively, it is
possible that miRs may stabilise AR transcript in an AGO2-
independent manner.
A potential mechanism of persistent cell survival under
conditions of depleted circulating androgens in CRPC is
expression of AR variants (AR-Vs) that are constitutively
active, lacking the LBD but retaining N-terminal transacti-
vation and DNA-binding domains [28]. AR variants, such
as AR-v7 and AR-v567es, drive overlapping but distinct
gene sets to wild-type AR [28]. AR-v1, -v4, -v7 and -v9
lack the C-terminal exon (exon 8), and thus have entirely
distinct 3′UTRs from WT transcript. These variants lack the
miR-346 and -361-3p binding sites present in WT-AR 3′
UTR, but contain an additional variant-specific miR-361-3p
site (Table S3). In contrast, ARv567es lacks exons 5–7 of
the LBD, but retains exon 8 (and an additional exon 9). It
thus has a 3′UTR longer than, but with high sequence
similarity to, WT-AR, retains WT miR-346 and -361-3p
binding sites and also has an additional miR-346 site at the
3′ end of its 3′UTR (Table S3). To assess effects of miR-
346 and -361-3p on AR variant mRNA levels, we used
22RV1 cells, which express the majority of described AR
variants, and C42 cells, which express AR-v7 only. It was
Fig. 1 High-throughput microRNA inhibitor screening identified
microRNAs that modulate androgen receptor signalling in prostate
cancer (PC) cells. a Schematic illustration of AR reporter construct and
derivative cell lines used for miR inhibitor screening. b Venn diagram
illustrating common hits between LNCaP and C42 cells. c Correlation
of miR hit scores between LNCaP and C42 cells. d–f Luciferase assay
analysis of AR activity in LNCaP (i, ii) and C42 (iii, iv) cells trans-
fected with 0–20 nM miR-346 (d), miR-361-3p (e) or miR-197-3p (f)
inhibitor (i, iii) or mimic (ii, iv) for 24 h. Mean of three independent
experiments ± SEM is shown. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0001.
See also Supplementary Table 2
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found that miR-346 inhibition reduced WT, v7 and v567es
expression in 22RV1 cells, with significance reached for
AR-v7. Similarly, miR-346 inhibitor significantly decreased
AR-WT and -v7 expression in C42 cells (Fig. S4a, b, see
also Fig. 2a). Very similar results were obtained for miR-
361-3p (Fig. S4c, d). To examine effects of miR-346 and
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-361-3p inhibition on WT and variant-AR protein levels,
Western blotting was performed in 22RV1 cells, WT-knock
out derivatives (22RV1-AR-FL-KO—all variants expressed
but not WT), parental CWR-R1-AD1 cells (lacking AR-
v567es) and the CWR-R1-D567es derivative lacking WT-
AR but overexpressing v567es. An N-terminal AR antibody
was used in order to detect both WT and variant-AR. This
antibody is unable to identify individual variants, although
AR-v567es is distinguishable from others due to its size
(80.7 kDa vs. 50.6–74.9 kDa for variants 1, 4, 7 and 9 and
110 kDa for WT-AR). Of note: the 22rv1 line carries a
35 kb tandem duplication encompassing AR exon 3 and
cryptic exons, which are spliced as alternative 3′ exons of
AR-variants, including v7 [29]. This may result in increased
levels of cryptic exon-derived variants in this cell line,
potentially in different ratios compared to cells lacking the
duplication. These, as above, are indistinguishable using
available antibodies. It was shown that miR-346 inhibitor
reduces protein levels of full-length and multiple variants of
AR (including v567es) across the above panel of cell lines
after 24 h (Fig. 2g). MiR-361-3p inhibitor produced similar
results, demonstrating a greater extent of repression (Fig.
2h). Biological replicates are shown in Fig. S5. Thus we
conclude that miR-346 and miR-361-3p modulation alters
levels of constitutively active AR variants in PC, and may
contribute to persistent AR signalling in CRPC in the
absence of circulating androgens.
AR-modulatory MiRs stabilise AR transcript and
their inhibition demonstrates additive effects with
AR silencing
In light of their effects on AR protein levels (Fig. 2b), we
investigated the ability of AR-modulatory miRs to enhance
AR transcript stability. C42 cells were transfected with miR
mimics for 24 h prior to 4 h Actinomycin D (ActD) treat-
ment. In agreement with Fig. 2a, all three miRs increased
AR mRNA levels in vehicle-treated conditions compared to
negative control (Fig. S2g). It was demonstrated that addi-
tion of either miR-346 or miR-197 rescued ActD-mediated
loss of AR transcript compared to negative control-
transfected cells in a significant manner, while miR-361-
3p transfection was not able to rescue ActD-mediated AR
mRNA loss (Fig. S2g). Given that miR-346, -361-3p and
-197 have profound effects on AR protein levels and
activity in PC cells, we hypothesised that modulation of
these miRs may alter PC cell proliferation, and that miR
inhibition may demonstrate combinatorial effects with AR
silencing, potentially revealing a novel therapeutic avenue
for PC treatment. To this end, LNCaP cells expressing a
doxycycline (Dox)-inducible AR siRNA [30] were treated
± 1 µM Dox and transfected with miR-346 or -361-3p
inhibitors or mimics prior to SRB cell proliferation analysis.
It was shown that miR-346 inhibitor alone significantly
reduced cell number to 40% of day 0 numbers (Fig. 3ai),
suggesting that miR-346 inhibition has cytotoxic, rather
than cytostatic effects. AR siRNA alone reduced growth of
LNCaP cells by ~50% over 6 days (Fig. 3a). Induction of
AR siRNA in the presence of miR-346 inhibitor did not
enhance effects of miR-346 inhibitor alone, presumably due
to the very marked effects of miR-346 inhibitor at con-
centrations used in this experiment (20 nM) (Fig. 3ai).
Converse experiments showed that miR-346 mimic was
able to significantly enhance proliferation of LNCaP cells
by 80%, and partially rescue effects of AR silencing in a
significant manner (Fig. 3aii). Inhibition of miR-361-3p
significantly repressed growth of LNCaP cells by 70%, and
further addition of AR siRNA in combination repressed cell
growth at day 6 to day 0 levels (Fig. 3bi). MiR-361-3p
mimic significantly increased proliferation of LNCaP cells
and partially rescued AR siRNA-induced reduction in cell
growth in a significant manner (Fig. 3bii). It was addition-
ally demonstrated that while miR-346 inhibitor represses
C42 and LNCaP proliferation at both 5 nM and 20 nM
Fig. 2 MiR-346, -361-3p and -197-3p alter wild-type and variant
androgen receptor activity in prostate cancer (PC) cells partially
through association with AR 3′UTR. a qRT-PCR analysis of AR
mRNA levels in C42/MAR4 cells transfected with (i) miR-346, (ii)
miR-361-3p or (iii) miR-197-3p mimic and/or inhibitor for 24 h.
bWestern blot analysis of AR protein levels in C42/MAR4 transfected
with (i) miR-346, (ii) miR-361-3p or (iii) miR-197-3p mimic and/or
inhibitor for 24 h. β-actin was used as a control for loading. Repre-
sentative blots of three independent experiments are shown. Additional
biological replicates and densitometry for three independent experi-
ments are shown (Fig. S1c–g). c qRT-PCR analysis of PSA mRNA
levels in LNCaP/MAR4 cells transfected with (i) miR-346, (ii) miR-
361-3p or (iii) miR-197-3p mimic and/or inhibitor for 24 h. L19 was
used as a normalisation gene. d, e Luciferase assay analysis of 6.9 kb
AR 3′UTR activity in HEK293T (d) or C42 (e) cells transfected with
pMiR-Report vector containing WT (d) or miR binding site-mutant (e)
regions of the AR 6.9 kb 3′UTR as depicted (Fig. S2Di) ± miR mimics
or inhibitors (20 nM) for 48 h (d) or 72 h (e) Luciferase activity was
normalised to β-galactosidase activity to correct for transfection effi-
ciency. Columns: mean normalised AR reporter luciferase activity
from three independent experiments performed in duplicate ± SEM.
f AGO2/biotin-miR RNA-IP analysis of miR-197 and miR-346 asso-
ciation with AR 6.9 kb 3′UTR. 22RV1 cells transfected with biotin-
labelled miR (200 pmol) for 24 h, followed by two-step immunopre-
cipitation with AGO2 antibody- and streptavidin-coated beads. RNA
was extracted from input and IP samples and qRT-PCR performed for
6.9 kb AR 3′UTR. Data are presented relative to input values. g, h
Western blot analysis of wild-type AR (110 kDa) and variant-AR
(65–90 kDa) in (i) CWR-R1-D567es (lacking WT-AR but over-
expressing v567es), (ii) CWR-R1-AD1 (parental cells expressing WT-
and variant-AR), (iii) 22RV1 (expressing WT- and variant-AR) and
(iv) 22RV1/AR-FL-KO cells (expressing AR-variants but with WT-
AR knocked out) cells transfected with (a) miR-346 or (b) miR-361-
3p inhibitor (both 20 nM) for 24 h. β-actin was used as a control for
loading. Representative western blot images are shown. See Fig. S5 for
independent biological replicates. *P ≤ 0.05, **P ≤ 0.005, ***P ≤
0.0001. See also Figs. S1, S2, S3, S4 and S5
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(Fig. S6a), miR-361-3p inhibitor reduced cell number in a
dose-dependent manner in both lines (Fig. S6c). In contrast
to the observed increase in LNCaP cell proliferation
following transfection of 7.5 nM miR-346 mimic, con-
centrations of 10 and 50 nM miR-346 mimic significantly
reduced proliferation of both C42 and LNCaP cells (Fig.
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S6b). We hypothesise that this is due to threshold effects of
miR-346 manipulation, with lower doses activating pro-
liferative responses, while higher concentrations induce
toxicity, leading to apoptotic induction as illustrated in Fig.
4a. Such a threshold is likely to be different in different cell
lines. MiR-361-3p mimic significantly increased C42 and
LNCaP cell growth at both 10 and 50 nM (Fig. S6d).
Interestingly, both miR-346 and -361-3p inhibitors sig-
nificantly repressed proliferation of AR-negative DU145
cells in a dose-dependent manner (Fig. 3c), suggesting that
at least some of miR-346 and -361-3p effects are mediated
via non-AR pathways.
We further investigated the ability of miR-346, 1361-3p
and -197 to regulate proliferation of AR variant-driven PC
cell lines, by comparing proliferation between parental
22RV1 cells (all variants and WT expressed) and WT-
knock out derivatives (22RV1-AR-FL-KO), and also
between parental CWR-R1-AD1 cells (lacking AR-v567es)
and the CWR-R1-D567es derivative lacking WT-AR but
overexpressing v567es. Interestingly, miR-346 inhibition
significantly reduced proliferation of 22RV1 cells expres-
sing variants only, but had less effect on the parental cells
with FL AR (Fig. 3d). Although the enhanced effect is
modest, it may reflect the additional miR-346 seed com-
plementarity site present in AR-v567es 3′UTR (nts 8353-
8358)—see Table S3. This is supported by the observation
that miR-346 inhibition non-significantly represses AR-
v567es-driven growth of CWR-R1-D567es cells, with no
effect observed in parental cells (Fig. 3e). MiR-361-3p
inhibition completely blocked proliferation of 22RV1 and
the variant-driven derivative, with similar effects in v567es-
driven CWR-R1 (Fig. 3f, g). This is consistent with effects
in LNCaP, C42 and DU145 cells (Fig. 3a–c, Fig. S6c, d),
and presence of similar numbers of miR-361-3p seed
complementarity sites in 3′UTRs of AR-variants and -WT
(Table S3).
We additionally investigated the ability of AR-
modulatory miRs to modulate apoptosis and apoptotic
response to AR silencing. It was demonstrated that miR-
346, -361-3p and 197 inhibitors significantly enhanced AR
siRNA-induced AR loss at transcript level, while AR
mRNA was significantly rescued by addition of miR
mimics in the presence of AR siRNA (Fig. 3h and Fig. S6e).
Accordingly, levels of AR targets PSA, TMPRSS2 and
KLK2 were significantly reduced following miR-346, -361-
3p of 197 inhibition in the presence of AR siRNA compared
to AR siRNA alone, while miR mimics rescued this (Fig. 3j,
S6f–h). MiR-346 inhibition significantly increased AR
siRNA-induced apoptosis by 85-fold, while miR-346 mimic
significantly reduced such apoptosis (Fig. 3ki). Likewise,
miR-361-3p significantly increased apoptosis of LNCaP
cells by fourfold compared to untreated cells, and sig-
nificantly enhanced apoptosis induced by AR siRNA by
sixfold, with a 50% reduction in apoptosis observed for
miR-361-3p mimic compared to AR siRNA alone (Fig.
3kii). In addition, miR-197 inhibitor significantly increased
apoptosis tenfold compared to untreated cells, and sig-
nificantly enhanced AR siRNA-induced cell death by 8.5-
fold, whereas miR-197 mimic reduced AR silencing-
induced apoptosis by 50% (Fig. 3kiii). Taken together,
these data indicate that miR-346 and -197 stabilise AR
transcript, and that miR inhibition shows additive effects
with AR silencing on proliferation and apoptosis, identify-
ing a rationale for potential combined use of AR-inhibitory
therapies and miR-346, -361-3p or -197 inhibitors in PC.
AR-modulatory MiR inhibition demonstrates
additive effects with enzalutamide
To provide further evidence to support the rationale of
combined miR-346, -361-3p or -197 inhibitor and anti-
androgen treatment, we investigated the effects of AR-
modulatory miR manipulation on apoptotic and pro-
liferative response to the anti-androgen, Enzalutamide
(Enza), in PC cells. It was demonstrated that miR-346
inhibitor significantly enhances apoptosis induced by Enza
by 52%, while miR-346 mimic (20 nM) also increased
Enza-induced apoptosis (Fig. 4ai), consistent with miR-346
mimic effects on proliferation in LNCaP cells at 10 and
50 nM (Fig. S6Bii). MiR-361-3p inhibitor significantly
increased Enza-induced apoptosis by 4.3-fold, while miR-
361-3p mimic significantly reduced Enza-induced apoptosis
by 40% compared to negative control-transfected, Enza-
Fig. 3 AR-modulatory miRs stabilise AR transcript and regulate
apoptosis and WT- and variant-AR-driven proliferation, and MiR-346,
-361-3p and -197-3p inhibitors show additive effects with AR silen-
cing. a, b SRB proliferation assay analysis of LNCaP/ARsiRNA cells
transfected with miR-346 (a) or miR-361-3p (b) mimic (7.5 nM –
miR-346, 20 nM – miR-361-3p) or inhibitor (10 nM – miR-346,
20 nM – miR-361-3p) ± 1 µM Dox to induce AR siRNA (ARKO) for
6 days. c SRB proliferation assay analysis of DU145 cells transfected
with miR-346 (i) or miR-361-3p (ii) inhibitor (5 and 20 nM) for
6 days. d–g SRB proliferation assay analysis of 22RV1 (di, fi),
22RV1-AR-FL-KO (AR variant-driven) (dii, fii), CWR-R1-AD1 (ei,
gi) and CWR-R1-D567es (AR-v567es-driven) cells (eii, gii) transfected
with: d, e miR-346 inhibitor (5 and 20 nM) or f, g miR-361-3p inhi-
bitor (5 and 20 nM) for 6 days. a–g Data are presented relative to
absorbance at day 0. Points: mean absorbance at 492 nm for three
independent experiments performed in quadruplicate ± SEM. h, j qRT-
PCR analysis of (h) AR and (j) PSA mRNA levels in LNCaP/
ARsiRNA cells transfected with miR-346 (i) or miR-361-3p (ii)
inhibitor or mimic (20 nM) ± Doxycycline (1 µM) for 24 h. L19 was
used as a normalisation gene. Columns: mean ± SEM for three inde-
pendent experiments performed in triplicate. k Caspase 3/7 Glo assay
analysis of apoptosis in LNCaP/AR siRNA cells ± miR mimic or
inhibitor (20 nM) ± Doxycycline (1 µM) for 72 h. Columns: mean
relative luminescence for three independent experiments performed in
triplicate ± SEM. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0001. See also Fig.
S6
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Fig. 4 AR-modulatory miRs inhibitors enhance enzalutamide efficacy.
a Caspase 3/7 Glo assay analysis of apoptosis in LNCaP/MAR4 cells
± miR-346 (i), miR-361-3p (ii) or miR-197-3p (iii) mimic or inhibitor
(20 nM) ± Enzalutamide (0.8 µM – in presence of inhibitors, 2 µM in
presence of mimics) for 72 h. Columns: mean relative luminescence
for three independent experiments performed in triplicate ± SEM. *P ≤
0.05, **P ≤ 0.005, ***P ≤ 0.0001. b SRB proliferation assay analysis
of LNCaP/MAR4 cells transfected with inhibitors of miR-346 (i –
2.5 nM), miR-361-3p (ii – 5 nM) or miR-197-3p (iii - 10 nM) or
mimics of miR-346 (iv – 10 nM), miR-361-3p (v – 30 nM) or miR-
197-3p (vi – 20 nM) ± Enzalutamide (0.8 µM) for 6 days. Data are
presented relative to absorbance at day 0 and one representative
experiment is shown. Additional biological replicates are shown in
Fig. S7
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treated cells (Fig. 4aii). Similar Enza-induced apoptosis-
modulatory effects were observed for miR-197 inhibitor and
mimic (Fig. 4aiii). We additionally investigated effects of
miR-346, -361-3p and -197 modulation on PC growth
inhibition by Enza. Inhibition of miR-346, -361-3p or -197
considerably enhanced Enza-induced reduction in LNCaP
proliferation (Fig. 4bi–iii). Conversely, miR-346 and -361-
3p mimics were able to completely rescue Enza-induced
repression of LNCaP proliferation (Fig. 4biv, v). MiR-197
mimic increased LNCaP/MAR4 proliferation, but did not
significantly alter cell growth in presence of Enza (Fig.
4bvi). Representative data is shown and results of replicate
experiments are shown in Fig. S7.
AR-modulatory MiR-361-3p increases migration and
invasion of PC cells and induces Snail-independent
EMT
Having demonstrated that miR-346, -361-3p and -197 mod-
ulate AR activity, proliferation and apoptosis in PC, we
hypothesised that these miRs may alter other cancer
progression-associated processes. To this end, transwell
migration assays were performed in C42 cells transfected with
miR-361-3p mimic or negative control mimic. It was
demonstrated that miR-361-3p significantly increases migra-
tion of PC cells by fourfold (Fig. 5a). In agreement with this,
miR-361-3p mimic also significantly enhanced C42 cell
migration when assessed by wound healing assay (Fig. 5b).
Further, miR-361-3p mimic was shown to increase invasion
of C42 cells through matrigel matrix (Fig. 5c), suggesting that
miR-361-3p overexpressing cells show increased capacity to
actively remodel extracellular matrix, potentially illustrative
of increased metastatic potential. Overexpression of neither
miR-197 nor miR-346 significantly increased invasion. To
investigate whether increased invasive potential is attributable
to adoption of a more mesenchymal PC cell phenotype (an
initiating event in metastasis), mRNA levels of the established
mesenchymal markers, Snail and ZEB2, were assessed in C42
cells post-miR-346, -361-3p or -197 transfection. mRNA
levels of both markers were significantly increased by a
minimum of 1.5-fold following miR overexpression (Fig. 5di,
ii). MiR overexpression also increased expression of addi-
tional mesenchymal markers, Slug and Twist-1 at mRNA
level (Fig. S8a), and concomitant loss of the epithelial mar-
kers, TSPAN-13 and E-Cadherin was observed following
miR-346 or -197 overexpression (TSPAN-13) and miR-346
or 361-3p overexpression (E-Cadherin) (Fig. 5diii, iv).
Similarly, while miR-346 and -361-1p mimics significantly
increased Snail and ZEB2 mRNA levels in LNCaP cells, their
inhibition led to reduction of these mesenchymal markers
(Fig. S8b, c).
To establish whether such gene expression changes
translated to modulation of EMT-associated protein levels,
Western blotting was performed to assess epithelial protein
levels in epithelial C42 cells and mesenchymal protein
levels in more mesenchymal-like PC3 and DU145 cells
following transfection of miR mimics and/or inhibitors. It
was demonstrated that overexpression of miR-346 and miR-
197 significantly reduced β-catenin and E-Cadherin protein
levels in C42 cells (Fig. 5e and S8E-iii). In support of
enhanced EMT by miR-346 and -361-3p, addition of miR
inhibitors in presence of miR mimics reduced protein levels
of the mesenchymal markers, N-Cadherin and Vimentin in
PC3 cells (Fig. 5f, Fig. S8d). Unexpectedly given increased
Snail mRNA levels in presence of miR mimics (Fig. 5di,
Fig. S8B), Snail protein levels were markedly induced, by
50-fold and 220-fold, respectively, following miR-346 or
-361-3p inhibitor transfection of PC3 cells in presence of
the corresponding miR mimic (Fig. 5f, Fig. S8d). Similar
significant effects were observed in the presence of miR
inhibitors alone (Fig. S8f): while most mesenchymal mar-
kers (N-Cadherin, Vimentin and Slug) are lost following
miR-346 or -361-3p inhibition, Snail levels are significantly
increased. To demonstrate that this was not a cell line-
specific effect, the more mesenchymal-like DU145 cells
were transfected with miR-346 or -361-3p inhibitor and/or
mimic. Again, Snail protein levels were significantly and
markedly increased in presence of miR inhibitors, an effect
rescued by addition of miR mimic (Fig. 5g, Fig. S9). In
contrast, protein levels of closely-related Slug are sig-
nificantly reduced in the presence of miR inhibitor (Fig. 5g,
Fig. S9), consistent with enhanced EMT in presence of miR
mimics and reversal of EMT when miRs are inhibited. We
hypothesised that this unique EMT protein signature may
result from direct regulation of Snail-regulatory proteins by
AR-modulatory miRs. Thus we mined AGO-PAR-CLIP
data from PC cells [31] for association of miR-346, -361-3p
or -197 with 58 unique Snail interactors identified from
biogrid.org. 20 of these (although not Snail itself) were
found to contain binding sites for at least one of AR-
modulatory miR-346, -361-3p or -197 in at least one PC cell
line. These include LATS, PARP1, MDM2, GSK3β and
PKCµ (Fig. S10a, Fig. 5h). We hypothesised that AR-
modulatory miRs may repress positive regulators (green
arrows, Fig. 5h) and upregulate negative regulators (red
arrows, Fig. 5h) of Snail protein levels in PC cells, with
miR inhibitors showing opposing effects. To confirm this
hypothesis, Western blotting was performed following
transfection of C42 cells with miR-346, -361-3p or 197
mimics. It was demonstrated that, as hypothesised, levels of
positive Snail regulators PARP1 and MDM2 were reduced
following transfection of miRs for which AGO-PAR-CLIP-
identified association in PC cells (Fig. 5i, Fig. S9b, c, d). In
addition, increased levels of negative Snail regulators,
GSK3β and PKCµ were identified following transfection of
AGO-PAR-CLIP-implicated miRs (Fig. 5i, S9b, c, d).
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These data confirm that AR-modulatory miR-346, -361-3p
and -197 can target Snail regulators, potentially contributing
to Snail-independent EMT in PC.
MiR-346, -361-3p and -197 downregulate the AR
corepressors, ARHGDIA and TAGLN2, and
upregulate the oncogene, YWHAZ, in PC
We have observed non-AR-mediated effects of miR-346,
-361-3p and -197 in PC. Given that pathway analysis
revealed additional roles for these miRs in such processes as
signal transduction, cell cycle and DNA replication (Fig.
S12), we sought to identify additional relevant targets of
miR-346, -361-3p and -197. Top AGO-PAR-CLIP targets
identified in at least three of five PC cell lines are shown
(Tables S4, 5 and 6). ARHGDIA, TAGLN2 and YHWAZ
were selected for further analysis based on their interaction
with at least one of miR-346, -361-3p or -197 in multiple
PC cell lines (Table S7), and also their links to PC pro-
gression or AR signalling. The majority of miR binding
sites identified were located within the 3′UTR of these
genes. ARHGDIA was identified as a target of miR-346 in
three PC cell lines, and as a miR-361-3p target in four lines
(Table S7). TAGLN2 3′UTR was identified as a miR-361-
3p and -197 target in four cell lines. Interestingly, TAGLN2
pseudogene, TAGLN2P1, was also identified as a miR-197
target in two PC lines (Table S7). It is tempting to speculate
that TAGLN2 pseudogene could act as a miR sponge to
regulate activity of TAGLN2. Finally, miR-346 3′UTR
binding sites were identified in YWHAZ 3′UTR in four PC
cell lines, while promoters of YWHAZ pseudogenes,
YWHAZP2 and YWHAZP7, were found to contain miR-
346 binding sites (Table S7). To validate functional asso-
ciation of miRs with identified regions of seed com-
plementarity, C42 cells were transfected with reporter
vectors containing ARHGDIA, TAGLN2 or YWHAZ 3′
UTRs downstream of Renilla luciferase, ±miR mimics or
inhibitors. MiR-346 significantly reduced ARHGDIA 3′
UTR activity, while inhibitor alone significantly increased
3′UTR activity by 15% (Fig. 6ai). MiR-346 increased
YWHAZ 3′UTR activity, which was partially rescued by
addition of miR-346 inhibitor (Fig. 6av), but did not sig-
nificantly alter activity of empty pLightSwitch, or vector
containing random 3′UTR in C42 (Fig. S11Aii) or
HEK293T cells (Fig. S11Bi,ii). MiR-361-3p significantly
reduced TAGLN2 3′UTR activity in C42 cells, with an
opposing increase in 3′UTR activity observed upon inhi-
bitor transfection (Fig. 6aiii), while it enhanced ARHGDIA
3′UTR activity (Fig. 6aii). This may be due to off-target
effects on the vector, as miR-361-3p increased luciferase
activity both of empty pLightSwitch and vector containing a
random 3′UTR sequence (Fig. S11A). Finally, miR-197
mimic significantly reduced 3′UTR activity of TAGLN2,
which was significantly opposed through addition of
miR-197 inhibitor (Fig. 6aiv). Similar results were obtained
upon repetition of experiments in HEK293T cells (Fig.
S11biii-iv).
To confirm miR targeting of 3′UTRs through association
with AGO-PAR-CLIP-identified seed region binding sites,
key residues within such seed binding sites were mutated
(minimum of three residues within seed-complementary
region) and 3′UTR luciferase reporter assays performed ±
miR mimics. AGO-PAR-CLIP-identified miR-346 seed
Fig. 5 AR-modulatory miRs modulate migration and invasion and
induce a unique EMT progression phenotype through modulation of
snail-regulatory proteins. a Transwell migration assay analysis of C42
cells transfected with miR-361-3p mimic (20 nM) for 48 h prior to
seeding onto rat tail collagen-coated transwell membranes for 48 h.
Representative image shown in (i), (ii) shows Columns: mean
migrated cell number for three independent experiments performed in
duplicate normalised to cell number by SRB proliferation assay ±
SEM. b Wound healing assay analysis of C42 cells transfected with
negative control or miR-361-3p mimic (20 nM) for 0–72 h. Repre-
sentative image shown in (i), in (ii) data are presented as % of day 0
wound remaining and represent mean ± SEM for three independent
experiments performed in triplicate (ii). c Matrigel invasion assay
analysis of C42 cells transfected with miR-346, -361-3p or -197-3p
mimic (20 nM) for 48 h prior to seeding onto rat tail collagen- and 5 µg
matrigel-coated transwell membranes for 48 h. Columns: mean
migrated cell number for three independent experiments performed in
duplicate normalised to cell number by SRB proliferation assay ±
SEM. d qRT-PCR analysis of Snail (i), ZEB2 (ii) TSPAN-13 (iii) and
E-Cadherin (iv) mRNA levels in C42 cells transfected with miR-346,
-361-3p or -197-3p mimics (20 nM) for 96 h. L19 was used as a
normalisation gene. Columns: mean ± SEM for three independent
experiments performed in triplicate. e Western blot analysis of the
epithelial markers β-catenin and E-Cadherin in C42 cells transfected
with miR-346, -361-3p or -197-3p mimic (20 nM) for 72 h. β-actin was
used as a control for loading. Representative blots of three independent
experiments are shown in (i). Images from replicate experiments may
be found in Fig. S8E. Densitometry was performed using Image J
software and relative protein levels are displayed (ii and Fig. SEii). f
Western blot analysis of mesenchymal marker proteins Snail, N-
Cadherin and Vimentin in PC3 cells transfected with miR-346 or -361-
3p mimic (20 nM) ± inhibitor (20 nM) for 96 h. β-actin was used as a
control for loading. Densitometry was performed using Image J soft-
ware and relative protein levels are displayed below bands and in Fig.
S8F. g Western blot analysis of mesenchymal marker proteins, Snail
and Slug, in DU145 cells transfected with miR-346 or -361-3p inhi-
bitor (20 nM) ± mimic (20 nM) for 48 h. β-actin was used as a control
for loading. Representative blots of three independent experiments are
shown. Images from replicate experiments may be found in Fig. S9.
Densitometry was performed using Image J software and relative
protein levels are displayed (Fig. S9). h MiR-346, -361-3p and -197-
3p prostate cancer (PC) AGO-PAR-CLIP targets were enriched for
Snail-regulatory proteins. Interactions and direction of modulation by
miRs is shown. MiR binding sites from AGO-PAR-CLIP are shown in
Fig. S10A. i Western blot analysis of Snail-regulatory proteins in C42
cells transfected with miR-346, -361-3p or -197-3p mimic (20 nM) for
96 h. β-actin was used as a control for loading. Representative blots of
three independent experiments are shown and P-values are indicated
by asterix. Images from replicate experiments may be found in Fig.
S10b–d. Densitometry was performed using Image J software and
relative protein levels are displayed (Fig. S10b–d). *P ≤ 0.05, **P ≤
0.005, ***P ≤ 0.0001. See also Figs. S8, S9 and S10
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Fig. 6 MiR-346, -361-3p and 197-3p repress known tumour sup-
pressors and upregulate the oncogene, YWHAZ in prostate cancer
(PC). a Luciferase 3′UTR reporter assay analysis of C42 cells trans-
fected with pLightSwitch (i), pLightSwitch-random-3′UTR (ii),
pLightSwitch-ARHGDIA-3′UTR (iii), pLightSwitch-TAGLN2-3′
UTR (iv) or pLightSwitch-YWHAZ-3′UTR (v) ± miR-346, -361-3p or
-197-3p mimics and/or inhibitors (20 nM) for 48 h. b Luciferase 3′
UTR reporter assay analysis of C42 cells transfected with wild-type or
miR binding site-mutant pLightSwitch-ARHGDIA-3′UTR (i),
pLightSwitch-TAGLN2-3′UTR (ii) or pLightSwitch-YWHAZ-3′UTR
(iii)±miR-346, -361-3p or -197-3p mimic, as appropriate, for 48 h. a,
b Luciferase activity was normalised to β-galactosidase activity to
correct for transfection efficiency, and data are displayed relative to
negative control miR-transfected cells. Columns: mean relative lumi-
nescence from three independent experiments performed in duplicate
± SEM. c Western blot analysis of TAGLN2, ARHGDIA and
YWHAZ protein levels in C42 cells transfected with miR-346, -361-
3p or -197 mimic (20 nM) for 96 h. β-actin was used as a control for
loading and replicate blots are shown (Fig. S10c). d AGO2/biotin-miR
RNA-IP analysis of miR-197 and miR-346 association with (i)
ARHGDIA, (ii) TAGLN2 and (iii) YWHAZ 3′UTRs. 22RV1 cells
were transfected with biotin-labelled miR (200 pmol) for 24 h, fol-
lowed by two-step immunoprecipitation with AGO2 antibody- and
streptavidin-coated beads. RNA was extracted from input and IP
samples and qRT-PCR performed for ARHGDIA, TAGLN2 and
YWHAZ. Data are presented relative to input values. Columns: mean
pulldown relative to input from three independent experiments ± SEM.
*P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0001. See also Figs. S11, S11 and
S13, and Supplementary Tables 3, 4, 5 and 6
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binding sites at nucleotides 556–562 and 1084–1091 of the
ARHGDIA 3′UTR. The more 5’ site shows greater con-
servation across mammals than the 3′ site. Mutation of each
site individually, and of both sites in the same vector, was
performed. Mutation of either region was able to completely
abolish miR-346 induced loss of ARHGDIA 3′UTR activ-
ity. Interestingly, although the extent of miR-346-induced
loss of 3′UTR activity was reduced following mutation of
both sites, complete rescue of repression was not observed
(as seen for individual sites) (Fig. 6bi). One poorly con-
served miR-197 binding site was identified by AGO-PAR-
CLIP at nucleotides 511–517 of TAGLN2 3′UTR. Mutation
of this seed-complementary region significantly abrogated
miR-197-induced loss of TAGLN2 3′UTR activity (Fig.
6bii). Finally, two miR-346 binding sites were identified by
AGO-PAR-CLIP at nucleotides 17–23 and 1713–1720 of
YWHAZ 3′UTR, with the proximal site very highly con-
served across mammals, and the more distal site relatively
poorly conserved. Mutation of these seed-complementary
regions individually only minimally reduced miR-346-
induced increase in YWHAZ 3′UTR activity, although this
effect was greater for the proximal site (Fig. 6biii). How-
ever, mutation of both sites significantly abrogated miR-
346-mediated increase in YWHAZ 3′UTR activity
(Fig. 6biii).
To investigate whether altered miR target 3′UTR
activity upon miR transfection is translated into altered
protein levels, Western blots were performed in C42 cells
following transfection of miR-197, -361-3p or -346. It
was shown that miR-197 significantly reduced levels of its
putative target, TAGLN2, by 56% (Fig. 6ci, Fig. S11Ciii,
iv). Similarly, miR-361-3p significantly decreased protein
levels of TAGLN2 by 70%, and ARHGDIA by 59% (Fig.
6cii, Fig. S11Cii, iv). In addition, miR-346 significantly
reduced ARHGDIA protein levels by 74% but increased
YHWAZ protein by 1.2-fold (Fig. 6ciii, Fig. S11Ci, iv).
Finally, to confirm physiological association of miRs with
target transcripts, we performed AGO/biotin-miR RNA-
IP. It was found that levels of ARHGDIA transcript are
significantly enriched in 22RV1 cells following IP with
miR-346 as compared to miR-197 or non-targeting con-
trol (Fig. 6di). Although pulldown of TAGLN2 was
greater in presence of miR-197 compared to non-targeting
control, there was no significant enrichment when com-
pared to miR-346, which was not identified as targeting
TAGNL2 by AGO-PAR-CLIP in 22RV1 cells (Fig. 6dii).
In contrast, enrichment of YWHAZ was increased twofold
upon miR-346 transfection, compared to non-targeting
control or miR-197 (Fig. 6diii). Taken together, these data
confirm functional repressive targeting of ARHGDIA by
miR-346 and -361-3p and TAGLN2 by miR-361-3p and
-197, and upregulatory targeting of the PC oncogene,
YWHAZ, by miR-346.
Additional putative miR-346 targets (IL18, LIF, BTK
and TAP1), miR-361-3p targets (ATXN7L3, MAPT and
PRMT2) and -197 targets (ACVR1, TSPAN3, TUSC2), as
identified from miRTarBase, were validated in PC cells
through a combination of AGO/biotin-miR RNA-IP, qPCR
and western blotting (Fig. S13).
siRNA-mediated silencing of ARHGDIA, TAGLN2 and
YWHAZ phenocopies effects of MiRs (or MiR
inhibition) in PC
If ARHGDIA, TAGLN2 and YWHAZ represent physiolo-
gically relevant miR-346, -361-3p and -197 targets in PC,
we reasoned that siRNA-mediated silencing of these genes
should phenocopy effects of miR overexpression (or miR
inhibition in the case of YHWAZ, since miR-346 increases
YHWAZ 3′UTR activity and protein levels). To address
this, we first examined AR protein levels in LNCaP cells
transfected with several single siRNAs targeting ARHG-
DIA, TAGLN2 or YWHAZ. It was found that both
ARHGDIA siRNAs tested reduced ARHGDIA protein
levels by up to 80%, with AR protein levels concomitantly
increased by up to 4.5-fold (Fig. 7ai, Fig. S14a). Similarly,
TAGLN2 siRNAs reduced TAGLN2 protein levels by up to
90% and increased AR protein levels up to 10.5-fold (Fig.
7aii, Fig. S14b). Interestingly, YWHAZ siRNAs reduced
YWHAZ protein levels by up to 70%, but contrasting effects
were observed on AR protein: where siRNAs efficiently
reduced YWHAZ protein levels (for example, siRNA #8 and
pooled siRNAs), AR protein levels were reduced by up to
60% (Fig. 7aiii, Fig. S14c), while less efficient silencing of
YWHAZ (for example, by siRNAs #3 and #6) led to a small
increase in AR protein levels of up to 20%, suggestive of
threshold effects of YWHAZ on AR protein levels. These
data demonstrate that siRNA-mediated silencing of
ARHGDIA and TAGLN2 phenocopies miR-346, -361-3p
and -197-induced increase in AR protein levels.
In support of the above data, siRNA silencing of
TAGLN2 significantly increased AR mRNA levels and
expression of the AR target gene, PSA, similar to effects
observed for the TAGLN2-targeting miRs 361-3p and 197
(Fig. 7b). As anticipated, siYWHAZ phencopied effects of
miR-346 inhibition, resulting in significant reduction of
both AR and PSA mRNA levels (Fig. 7b). siRNA silencing
of ARHGDIA did not significantly modulate AR mRNA
levels, but unexpectedly and significantly reduced PSA
levels in LNCaP cells (Fig. 7b). To ascertain whether
siRNA silencing of miR targets can replicate phenotypic
effects of miR manipulation, SRB assays were performed in
LNCaP cells following transfection of ARHGDIA,
TAGLN2 or YWHAZ siRNAs. It was demonstrated that
knockdown of ARHGDIA increased cell number by 1.3-
fold (Fig. 7ci) and that TAGLN2 siRNA enhanced
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proliferation by 1.25-fold (Fig. 7cii). In contrast, knock-
down of YWHAZ significantly reduced LNCaP cell pro-
liferation by 20% (Fig. 7ciii). Taken together, these data
demonstrate that targeting of ARHGDIA, TAGLN2,
YWHAZ are likely to significantly contribute to oncogenic
miR-346, -361-3p and -197-induced phenotypes.
To examine the relevance of AR-modulatory miR
expression and levels of their targets genes to clinical PC
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development and progression, bioinformatic analyses of
publically available expression data sets were performed.
Upon examination of AR-modulatory miR levels in fresh-
frozen tissue from five PCs and six normal prostates
(GSE34932), it was found that miR-197 was significantly
decreased in cancer vs normal, while miR-361-3p is
unchanged and miR-346 significantly increased (Fig. 7d).
TAGLN2 mRNA levels were significantly lower in cancer
vs normal and ARHGDIA and YWHAZ levels elevated
significantly and non-significantly, respectively, in the same
data set (Fig. 7e). In analysis of TCGA-PRAD data from
333 primary PCs, increased YWHAZ transcript correlated
with Gleason grade in a highly-significant manner (Fig. 7fi),
and was higher in patients with lymph node metastases,
biochemical recurrence and in non-organ-confined disease
(Fig. S15). No such relationships were identified for
TAGLN2 or ARHGDIA. In the same data set, miR-346, but
not -361-3p nor -197, was significantly elevated in lymph
node-positive disease (Fig. 7fii). As anticipated, ARHGDIA
expression inversely correlated with its targeting miRs,
miR-346 and miR-361-3p, in the TCGA-PRAD data set
(Fig. S16a, b). However, miR-361-3p was found to posi-
tively correlate with its target, TAGLN2 (Fig. S16c), and
miR-346 negatively correlated with its positively regulated
target, YWHAZ (Fig. S16d). When linear regression ana-
lysis was conducted to assess correlation between AR
activity score and miR targets in CRPC patient tumours
(n= 122) from SU2C [32], a significant positive correlation
of ARHGDIA expression with AR activity was found (P=
5 × 10−8) (Fig. 7gi), while TAGLN2 is significantly nega-
tively correlated (P= 0.03) (Fig. 7gii). Similarly, YHWAZ
is negatively associated with AR activity, although samples
separate into two populations according to YWHAZ
expression, and both correlate positively with AR activity
when assessed individually (Fig. 7giii). In the same data set,
patients with high levels of miR-197 showed a near-
significant (P= 0.0501) decreased survival compared to
miR-197 low patients (Fig. S16e). Neither miR-346 (Fig.
S16f) nor miR-361-3p (alone, Fig. S16g, or combined with
miR-197, not shown) correlated with survival in TCGA-
PRAD. Of note, MiR-361-3p significantly correlated with
AR activity in this cohort (Fig. S16h), albeit with an r2
value of 0.13.
We next investigated the effect of treatment on AR-
modulatory miRs in patient-derived models. CP50 PDX
was derived from a CRPC patient biopsy with chromosome
8 gain and AR amplification who had progressed through
all standard of care therapies (Welti et al; submitted to
Clinical Cancer Research). Short-term (10 days) treatment
with enzalutamide (10 mg/kg; n= 3) did not significantly
alter miR levels compared to vehicle treatment (Keptose
HPB; n= 3) (Fig. 7Hi). However, long-term treatment
(mean 35.5 days) with enzalutamide (n= 6) resulted in
significant increases in miR-197 and -361-3p levels as
compared to vehicle (n= 6) (Fig. 7hii). MIR-346 levels
were not altered (Fig. 7hii).
Taken together, these data confirm that AR-modulatory
miRs and their biologically relevant PC targets are altered in
cancer vs normal tissue, correlate with disease progression
and AR activity, and are altered in response to hormone
therapy in a CRPC patient tumour.
Discussion
In PC that is refractory to conventional LBD-targeting anti-
androgens, AR-targeting miRs may represent promising
therapeutics or drug targets. A handful of studies have
demonstrated direct AR targeting by miRs, however with
little consensus. Much remains to be learnt regarding the
roles of miRs and the AR 3′UTR in disease progression, the
ability of miRs to integrate AR signalling with other path-
ways, and relationships between AR and other targets of
AR 3′UTR-associating miRs. In an effort to increase con-
sensus on AR-modulatory miRs, we performed a miR
inhibitor library screen in LNCaP and C42 PCa cells stably
expressing a luciferase-based AR activity reporter.
Fig. 7 AR-modulatory miR target siRNA silencing phenocopies miRs.
a Western blot analysis of ARHGDIA, TAGLN2, YWHAZ and AR
protein levels in LNCaP cells transfected with siRNAs (1 or 10 nM)
targeting (i) YWHAZ, (ii) TAGLN2 or (iii) ARHGDIA for 72 h. A
minimum of two different siRNAs were used for each gene. β-actin
was used as a control for loading. b qRT-PCR analysis of (i) AR or (ii)
PSA mRNA levels in LNCaP cells transfected with ARHGDIA,
TAGLN2 or YWHAZ siRNAs (10 nM) for 48 h. L19 was used as a
normalisation gene. Columns: mean ± SEM for three independent
experiments performed in triplicate. c SRB proliferation assay analysis
of LNCaP cells transfected with siRNA targeting ARHGDIA,
TAGLN2 or YWHAZ (10 nM) for 6 days. Data are presented relative
to absorbance at day 0. Points: mean absorbance at 492 nm for three
independent experiments performed in quadruplicate ± SEM. d, e
MiR-197 (di), miR-346 (dii), miR-361-3p levels (diii), TAGLN2 (ei),
ARHGDIA (eii) and YWHAZ (eiii) RNA levels in fresh-frozen tissue
from five PCs and six normal prostates (GSE34932). f YWHAZ
mRNA levels in PC tumours of Gleason Grades 6–10 (i) and miR-346
levels in PC tumours of lymph node-positive and –negative patients
from the TCGA-PRAD data set of 333 primary prostate cancers (PCs).
g Linear regression analysis of correlation between AR activity and
ARHGDIA (i), TAGLN2 (ii) and YWHAZ (iii) levels in CRPC patient
tumours (n= 122, transcriptome data from SU2C-PCF). AR activity
score is an accumulation measurement of AR pathway activity based
on 43 genes whose expression level is regulated by AR in PC cell lines
[56] and metastatic PC [57]. h qRT-PCR analysis of miR-197, miR-
346 and -361-3p levels in patient-derived xenografts implanted into
nude mice and derived from a single biopsy from an AR-amplified, C-
MYC-gain CRPC patient. Enzalutamide (10 mg/kg) or vehicle treat-
ment was initiated when xenografts reached 300 mm3, and mice killed
at day 10 (i) or when tumours reached 100 mm3 (ii) (mean treatment
duration= 35.5 days). (i) n= 3 per treatment group, (ii) n= 6 per
treatment group. Data were normalised to U6 and SNORD48 levels.
*P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0001. See also Figs. S14, S15, S16
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Although little agreement was observed between top hits
from our screen and that of Kumar et al. [13], which used a
miR mimic library, 22 miR inhibitors that increased AR
activity above our stringent threshold in LNCaP and/or C42
cells agreed with their screen in that the corresponding miR
mimic significantly reduced LNCaP cell viability, and
decreased PSA and/or AR protein levels/ activity in at least
two of three PC cell lines tested (LNCaP, VCaP, LAPC4).
Four additional miRs, inhibitors of which decreased AR
activity in our screen, were likewise identified by these
criteria in the Kumar study. Of thirteen miRs found by
Östling et al. to significantly reduce AR 3′-UTR activity,
although corresponding inhibitors did not found to mod-
ulate AR activity above our threshold, there was some
agreement for seven, as we found that miR-421 and -449a
increased AR activity in C42 cells; miR-135b, -634 and
-654-5p increased AR activity in LNCaP; while miR-34c
and miR-9 increased AR activity in both lines. We were
unable to validate previously reported reduction of AR
levels, in various cell lines, by miR-185 [16], miR-34a [33],
or miR-488-5p [13, 19]. We identified agreement with our
screening data (LNCaP and/or C42) for 26 of 64 miRs
identified to modulate PSA protein levels in LNCaP and
LAPC4 cells in a miR mimic screen by Larne et al. [34],
although only three had B Score > 6 in our screen. There are
many likely reasons for lack of agreement between studies:
differences in library types (mimic or inhibitor), inhibitor/
mimic concentrations, cell lines with different transfection
efficiencies and endogenous miR levels, end-point assays,
and statistical scores and thresholds for analysis.
Upon validation of screen hits, we demonstrated that
miR-346, -361-3p and -197 inhibitors markedly reduced
AR activity in both LNCaP and C42 cells, with opposite
effects observed for corresponding miR mimics. In corro-
boration we also showed that the inhibitors significantly
reduced AR mRNA and protein levels, and target gene
expression, effects rescued by addition of miR mimics.
Since these effects were observed after only 24 h, it is likely
that these miRs directly regulate AR through activatory
association with the 3′UTR, in contrast to the classical
model of target repression by miRs. In support of this, we
identified binding sites for all three miRs in the extended
6.9 kb AR 3′UTR, which has been described in PC cells by
a number of studies [15, 27], but is not used by miR binding
prediction tools, which use the UCSC genome browser and
Genbank-defined 436 nt AR 3′UTR sequence
(NM_000044). This could potentially result in exclusion of
critical but uncharacterised regulators of AR activity from
previous investigations. Direct miR-346, -361-3p and -197
upregulation of AR 3′UTR activity was confirmed through
use of AR 3′UTR reporters in combination with miR
mimics, which significantly increased AR 3′UTR activity,
with specificity demonstrated through additional
transfection of miR inhibitors and miR seed binding site
mutagenesis. Such miR-mediated AR upregulation could
provide a mechanism for maintenance of AR activity in
castrate conditions. Further, miR-346 and -197 prevented
ActD-induced loss of AR transcript, so may additionally
repress AR mRNA turnover. This study is not the first to
report miR-346 upregulation of target genes: miR-346
increases AGO2 mRNA and protein levels in cervical,
gastric and colorectal cancer cell lines through formation of
a miR-346 mid-region ‘bulge’ upon association with AGO2
3′UTR, which in turn increases recruitment of GRSF1 [35].
The same authors showed that a similar mechanism
increases recruitment of miR-346-bound hTERT mRNA to
ribosomes to enhance translation in a GRSF1-dependent
manner [36]. It will be interesting to assess whether miR-
346:AR 3′UTR association results in similar miR looping
and recruitment of RNA binding proteins.
The identification of an extended AR 3′-UTR in PCa cell
lines is interesting in the context of a proposed novel
mechanism for altered gene regulation, whereby dynamic 3′
UTR shortening prevents miR targeting. In cancer cells,
mRNAs with shortened 3′-UTRs produced tenfold more
protein, in part due to loss of miR-mediated repression [37].
While it has been proposed that active AR 3′-UTR short-
ening represents a further mechanism of PCa progression
[38], permitting AR to evade regulation by tumour-
suppressive miRs, such miR-34a and miR-34c [15], there
is currently no evidence for reduced miR binding and
consequently higher AR protein levels following AR 3′-
UTR shortening. Further studies are required to assess its
potential role in cancer progression, especially given our
data showing AR 3′UTR as a region positively regulated by
oncogenic miRs.
Expression of constitutively active AR variants lacking
the LBD represent a potential mechanism of cell survival in
CRPC. AR-v7 has a distinct 3′UTR sequence from WT-
AR, while ARv567es 3′UTR has considerable overlap with
WT-AR 3′UTR but is extended at the 3′ end [39]. We
therefore hypothesised that ARv567es would be subject to
regulation through the same miR-346 and -361-3p binding
sites as WT-AR, while AR-v7 would not. Indeed, we
observed decreased ARv567es mRNA and protein levels
following transfection of miR-346 and miR-361-3p inhibi-
tors in 22RV1 and CWR-R1-D567es cells. AR-v7 mRNA
was significantly decreased following miR-361-3p inhibitor
transfection in 22RV1 and C42 cells, possibly due to an
AR-v7/9/4-unique miR-361-3p 7mer site between 981-
987nt of AR-v7 3′UTR (Table S3). AR-v7 does not contain
any predicted miR-346 binding sites however, and the
unexpected decrease in its expression in both 22RV1 and
C42 cells following miR-346 inhibitor transfection (Fig.
S4c) may be attributable to feedback regulation from loss of
WT-AR. Protein levels of AR variants of size consistent
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with AR-v1, -v4 and -v7 were markedly downregulated
upon miR-361-3p inhibitor treatment in 22RV1 and CWR-
R1-AD1 cells. Together, these data indicate that modulation
of miR-346 and miR-361-3p can alter levels of con-
stitutively active AR variants as well as WT/full-length AR.
Given their effects on AR activity, we examined phe-
notypic consequences using proliferation assays and found
that miR-346 and -361-3p inhibitors reduce proliferation,
supporting a tumour-promoting/oncogenic effect of the
corresponding miRs. In AR-positive cells the inhibitors
showed additive effects with AR silencing and Enzaluta-
mide treatment, conversely, mimics increased PC cell pro-
liferation and abrogated AR siRNA- or Enza-induced loss
of cell proliferation. This extended to AR-variant-driven
lines, and the enhanced effects of miR-346 inhibition on
AR-variant-driven vs parental PC cell growth likely reflect
the presence of an additional variant-specific miR-346 seed
complementarity site in v567es 3′UTR. However, miRs
have potentially dozens of target mRNAs, and the pheno-
typic consequences of miR inhibition are likely to be both
AR-mediated and non-AR-mediated Indeed, miR-346,
-361-3p and -197 inhibitors were able significantly reduce
growth of both AR-positive and AR-negative cells in a
dose-dependent manner. Looking into potential modes of
action by which miR-346, -361-3p and -197 inhibitors
reduce proliferation, we found that all three significantly
increased apoptosis in LNCaP cells, and enhanced cell
death induced by AR inhibition//ablation, while the mimics
mostly abrogated this. The observation that, contrary to
expectation, miR-346 mimic showed similar effects to
inhibitor in increasing Enza-induced apoptosis may be
attributable to very large (280,000-fold) upregulation of
miR-346 upon transfection of mimic at 20 nM final con-
centration (Fig. S1Ai), which may generate toxicity. Indeed,
10 nM miR-346 mimic was shown to repress C42 and
LNCaP proliferation, and cells showed signs of toxicity at
this concentration (Fig. S6b). All three inhibitors showed
additive effects with AR siRNA on AR target gene
expression, while corresponding mimics rescued AR
siRNA-mediated loss of AR, PSA and KLK2 expression.
However, the observation that they could not completely
rescue effects of AR siRNA on proliferation, apoptosis and
AR target gene expression supports that these miRs also
function, in part, through non-AR pathways. This is rein-
forced by the observation that miR-346 and -361-3p inhi-
bition significantly reduces proliferation of AR-negative
DU145 cells. Together, these data suggest that miR-346,
miR-361-3p and miR-197 can act as oncomiRs to increase
PC proliferation and inhibit apoptosis, partly, but not
wholly, through regulation of AR signalling.
As further evidence of its oncomiR function, miR-361-
3p significantly increases migration and invasion of C42 PC
cells. It is thus interesting that significant downregulation of
miR-361-3p was observed in prostatic secretions of 23 (low
grade) PC patients compared to 25 BPH controls [40]. It
would be interesting to know whether observed miR dys-
regulation was also identified in tissue, urine or plasma, and
whether the correlation is retained in men with higher-grade
tumours. Conceivably, these data may suggest active
retention of oncomiR-361-3p within PC cells, to drive EMT
and migration/invasion. Indeed, miR-361-3p, -346 and -197
all reduced levels of epithelial markers in C42 cells (which
have epithelial morphology), while miR-346 and -361-3p
inhibitors decreased protein levels of mesenchymal markers
in the more aggressive PC3 and DU145 cells. The exception
was Snail, a mesenchymal marker, which was markedly
increased. We hypothesised that miR-346, -361-3p and -197
modify levels of Snail-regulatory proteins, and analysis of
AGO-PAR-CLIP data confirmed these to be enriched in
their targets: Snail repressors GSK3β and PKCµ appear to
contain activatory miR binding sites (levels are increased in
presence of targeting miRs), while Snail activators MDM2,
PARP1 and LATS2 contain repressive miR binding sites.
An alternative, possibly complementary, explanation is that
the miRs induce intermediate EMT ‘plasticity’ that pro-
motes migration and invasion in a Snail-independent man-
ner. Evidence for such Snail-independent EMT has been
suggested by a number of studies: p38 MAP kinase and p38
interacting protein (p38IP) are required for E-Cadherin
downregulation during EMT in mouse embryo gastrulation,
in a Snail-independent manner [41]; Snail and Slug induce
distinct EMT programmes in mammary stem cells as
compared to tumour initiating cells [42]; and high levels of
the E-Cadherin repressors, ZEB1 and ZEB2, which could
initiate EMT independently of Snail, were found in recur-
rent oral squamous cell cancer as compared to primary
tumours, suggestive of non-canonical EMT progression in
advanced cancer [43].
To identify additional PC-relevant targets of these miRs
that mediate the non-AR-mediated effects, we exploited
AGO-PAR-CLIP to identify miR:target association in a panel
of PC cell lines. We focussed on genes previously implicated
in PC and with multiple 3′UTR binding sites for more than
one of miR-346, 361-3p and -197, selecting YWHAZ,
ARHGDIA and TAGLN2 for further analysis. Our data
confirm ARHGDIA and TAGLN2 as bona fide AR-
modulatory miR targets, downregulated by miR-346 and
-361-3p, and miR-361-3p and -197, respectively. ARHGDIA
and TAGLN2 have both previously been shown to repress
AR transcriptional activity, and to have tumour-suppressive
roles [44–47]; their downregulation has clear implications for
PC development, and further supports oncogenic activity of
miR-346, 361-3p and -197. Conversely, the androgen-
regulated PC oncogene YWHAZ was upregulated by miR-
346, likely through association between the miR and
nucleotides 17–23 of YWHAZ 3′UTR. YWHAZ has been
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shown to directly associate with AR, to promote proliferation,
migration, survival and resistance to apoptosis in PC cells
[48], to increase in PC patient tumours as compared to benign
tissue, and to positively correlate with presence of metastases
in clinical tumour samples [49]. Thus, miR-346-mediated
YWHAZ upregulation could enhance PC progression.
To confirm biological relevance of miR targeting of
ARHGDIA, TAGLN2 and YWHAZ, we examined the ability
of siRNAs against these genes to phenocopy effects of miR-
346, -361-3p and -197 in PC cells. Silencing ARHGDIA or
TAGLN2 resulted in increased AR protein levels, target gene
expression and PC cell growth, similarly to miR-346, -361-3p
or -197 mimics. Conversely, and as anticipated, siYWHAZ
phenocopied miR-346 inhibition reducing AR protein levels
and represseing PC cell growth. We hypothesise that AR-
modulatory miRs may have important functions at different
stages of PC: miR-346 levels are higher in cancerous vs
normal prostate tissue and elevated in tumours of patients
with lymph node metastases compared to those without, while
not altered in Enza-treated CRPC patient xenografts. In con-
trast, miR-197 is reduced and -361-3p unchanged in cancer-
ous vs normal prostate, but both were significantly elevated in
Enza-treated CRPC xenografts, although only after long-term
treatment. This suggests that while miR-346 may contribute
to progression of early-stage PC (through upregulation of
YWHAZ and AR activity), miR-197 and -361-3p may act at
the castrate-resistant stage of the disease to promote or
maintain resistance to AR-targetting therapies, through
downregulation of tumour-suppressive targets and stabilisa-
tion of AR transcript.
Taken together, these data identify miR-346, miR-361-
3p and miR-197 as AR-modulatory miRs in PC that
associate with an extended form of the AR 3′UTR to
increase transcript stability and AR activity. AR-modulatory
miRs modulate apoptosis, proliferation, EMT, migration
and invasion of PC cells, and their inhibition shows additive
effects with anti-androgens, highlighting the potential for
combination approaches for the treatment of PC. Silencing
PC-relevant miR targets phenocopies effects of these miRs,
supporting their physiological relevance.
Materials and methods
Mammalian cell culture
Cells were maintained at 37 °C in 5% CO2. PC3, 22RV1,
LNCaP, C42, DU145 and HEK293T cells were maintained
and passaged in RPMI-1640 or Dulbecco’s Modified
Eagle’s Medium (DMEM – HEK293T only) (Sigma) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 µg/ml streptomycin and 2mM L-glutamine
(Sigma). LNCaP/ARE, C42/ARE and DU145/ARE cells
were maintained and passaged as above but with 10%
tetracycline-free FBS, 12 µg/ml blasticidin and 500 µg/ml
G418. LNCaP/ARsiRNA cells (a kind gift of Paul Rennie,
Vancouver Prostate Centre, Canada) were maintained as
above, but with 2.4 µg/ml blasticidin and 1 µg/ml pur-
omycin. Parental 22RV1 cells and AR WT-knock out
derivatives, and parental CWR-R1-AD1 cells and CWR-
R1-D567es derivative lacking WT-AR but expressing AR-
v567es were kind gifts from Luke Gaughan, Newcastle
University, UK, and Scott Dehm, University of Minnesota,
USA, respectively [50]. Cell lines were routinely tested for
Mycoplasma contamination on a monthly basis
Plasmid stocks
pMiR-Report-AR 6.9 kb 3′UTR reporter plasmids 1–7,
representing seven different regions of the 6.9 kb AR 3′
UTR (Fig. 2d) were a kind gift from Dr Shawn Lupold(36).
pLightSwitch-Empty, pLightSwitch-Random#2,
pLightSwitch-ARHGDIA 3′UTR, pLightSwitch-TAGLN2
3′UTR and pLightSwitch-YWHAZ 3′UTR were purchased
from OriGene. Putative miR-346, -361-3p and -197-3p
binding sites were mutated in the above vectors by site-
directed mutagenesis using the QuikChange Lightning Site-
Directed Mutagenesis Kit (Stratagene).
High-throughput LNA microRNA inhibitor screening
C42/ARE and LNCaP/ARE cells were seeded into thirteen
96-well, white-walled, flat-bottomed cell culture plates per
cell line in hormone-depleted, antibiotic-free RPMI medium
48 h prior to transfection. Seeding densities were 3000 cells
per well (C42/ARE) and 4000 cells per well (LNCaP/ARE).
8 h prior to transfection, cells were supplemented with
0.1 nM Mibolerone. Cells were transfected with LNA
MicroRNA Inhibitor Library (Exiqon) to a final con-
centration of 20 nM using Lipofectamine RNAiMax for
48 h. Controls were AllStars Hs Cell Death Control siRNA
(Qiagen), AllStars Negative Control siRNA (Qiagen) and
LNA Negative Control A (Exiqon).
MicroRNA inhibitor/mimic, siRNA transfection
MiRCURY LNA microRNA inhibitors and mimics (Exi-
qon) and/or miRidian microRNA mimics (GE healthcare)
were transfected into cells at final concentration of 0–30 nM
in antibiotic-free conditions using Lipofectamine RNAiMax
as per the manufacturer’s recommendations. siRNAs (Flex-
itube, Qiagen) were transfected as above, final concentration
10 nM. Co-transfection of plasmids and siRNAs or micro-
RNA inhbitors/mimics was performed using JetPrime
transfection reagent (Polyplus) according to the manu-
facturer’s protocol.
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RNA extraction
RNA was extracted using Trizol according to the manu-
facturer’s specifications. For RNA extraction from PDX
tissue, samples were subjected to homogenisation using
Precellys24 Homogeniser in the presence of Trizol.
MiR and mRNA quantitative real-time PCR
Mature miR expression was quantified by quantitative real-
time RT-PCR using TaqMan microRNA assays and Taq-
Man Universal PCR Master Mix (Applied Biosystems)
according to the manufacturer’s protocol. For detection of
mRNAs, cDNA was prepared from 500 ng total RNA using
Precision qScript Reverse Transcription kit (PrimerDesign)
and oligo d(T) primers. cDNAs were amplified using 2×
Fast SYBR Green Master Mix (Applied Biosystems) and
250 nM forward and reverse primers (Table S1). All data
were analysed using the ΔΔCt method, with U18 and L19
as endogenous references for miR and mRNA levels
respectively, using DMSO/ethanol-treated samples as cali-
brators where appropriate.
3′UTR reporter assays
HEK293T or C42 cells seeded in 24-well plates were co-
transfected with 400 ng pMiR-Report AR 6.9 kb 3′UTR
#1–7, pLightSwitch-Empty, pLightSwitch-Random#2,
pLightSwitch-ARHGDIA 3′UTR, pLightSwitch-TAGLN2
3′UTR, or pLightSwitch-YWHAZ 3′UTR (Origene)
alongside 50 ng pdm-LacZ (β-galactosidase expression
vector) and 0–20 nM final concentration non-targeting,
miR-346, miR-361-3p or miR-197 mimic and/or inhibitors
(see above) using JetPrime Transfection reagent for 48 h.
For AR 3′UTR reporter assays, luciferase assays were
performed using Luclite assay as below. For pLightSwitch
plasmids, LightSwitch luciferase assay (Active Motif) was
used according to the manufacturer’s protocol. For both
assays, luciferase activity was normalised for transfection
efficiency using the Galacton kit (Tropix) as previously
described [51].
Luciferase assays
Luciferase assays were performed using the Luclite assay
(Packard, USA). Cell medium was aspirated from wells
and 30 µl (96-well plates) or 60 µl (24-well plates) of
Reporter Lysis Buffer (Promega) added per well. Plates
were stored at −80 °C for a minimum of 15 min. Plates
were thawed and 30 µl luciferin substrate added per well
(96-well plates) or 20ul of cell lysate dispensed in duplicate
into white-walled 96-well plates and 20ul luciferin sub-
strate added per well (24-well plates). Plates were
incubated for 15 min in the dark prior to luminescence
reading using the GloMax system (Promega) or Victor
luminescence counter. Luciferase activity was normalised
for cell number by Bradford assay for protein content,
where appropriate.
Actinomycin D transcriptional inhibition
experiments
C42 cells in 6-well plates previously transfected with miR
mimics for 24 h were treated with Actinomycin D (1 µg/ml)
for 4 h prior to harvesting and RNA extraction.
Cell Lysis, western blotting and antibodies
Cells were lysed and protein extracted as described [26].
Proteins were resolved by 8–12% SDS-polyacrylamide
gel electrophoresis and electroblotted to nitrocellulose
membrane (Bio-Rad). After blocking (5% non-fat dried
milk powder in 0.05% Tween-20 in 1x TBS) for 40 min,
membrane was incubated with mouse anti-androgen
receptor mAb (ThermoFisher, MA513426), rabbit anti-
beta-catenin pAb (Cell Signalling Technology, 8480),
rabbit anti-E-Cadherin pAb (Cell Signalling Technology,
3195), rabbit anti-Snail pAb (Cell Signalling Technology,
3879), rabbit anti-N-Cadherin pAb (Cell Signalling
Technology, 13116), rabbit anti-Vimentin pAb (Cell
Signalling Technology, 5741), rabbit anti-Slug pAb (Cell
Signalling Technology, 9585), rabbit anti-MDM2 mAb
(Abcam, ab178938), mouse anti-PARP1 mAb (Santa Cruz
Biotechnology, sc-8007), rabbit anti-PKCµ mAb (Abcam,
ab108963), mouse anti-GSK3β mAb (Abcam, ab93926),
rabbit anti-LATS2 pAb (Abcam, ab70565), rabbit anti-
ARHGDIA pAb (Santa Cruz Biotechnology, sc-360),
mouse anti-TAGLN2 mAb (Santa Cruz Biotechnology,
sc-373928), rabbit anti-YWHAζ pAb (Abcam, ab51129),
mouse anti-BTK mAb (R+D Systems, MAB5807),
mouse anti-LIF mAb (Abcam, ab34427), mouse anti-
β-tubulin mAb (Sigma, T4126), or mouse anti-β-actin
mAb (Abcam, ab6276) for 1 h and visualised using goat
anti-mouse, goat anti-rabbit, goat anti-rat or rat anti-goat
IgG-HRP as appropriate. Detection was by Luminata
Forte HRP substrate (Millipore).
Sulphorhodamine B (SRB) Assay
Cell number was assayed using the SRB assay as previously
described [52].
Luminescent caspase 3/7 activation assay
Caspase assays were performed using the Caspase-Glo 3/7 kit
(Promega) according to the manufacturer’s instructions, 48 h
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post-transfection with miR mimics or inhibitors. Luminescent
signal was detected using a Victor luminometer.
Wound healing assay
Cells seeded in 6-well plates were transfected with miR
mimics as described. 48 h post-transfection, an artificial
‘wound’ was created in the cell monolayer using a 200 µl
pipette. Medium was replaced with antibiotic-free, phenol
red-free RPMI supplemented with 5% sFCS to minimise
proliferation. Wounds were imaged at 0 and 24 h and
wound area quantified using Image J.
Transwell migration/matrigel invasion assays
Cells seeded in 6-well plates were transfected with miR
mimics as described. 48 h post-transfection, outer surfaces of
8 µm pore transwell inserts were pre-coated with 2.5 μg rat
tail collagen type I in cold, non-supplemented, phenol red-
free, RPMI and air-dried for 2 h and placed in 24-well
companion plates. Transfected cells were harvested and
seeded (3 × 104 cells per condition) onto collagen-coated
transwell membranes in 100 μl serum-free RPMI in dupli-
cate. Lower chamber of companion plate was filled with
600 μl antibiotic-free complete growth medium as a che-
moattractant. Cells were incubated for a further 48 h at
37 °C. Inner surfaces of transwells were scrapped with a
PBS-soaked cotton bud to remove non-migrated cells.
Migrated cells were fixed with 4% paraformaldehyde in PBS
for 10 min at RT, washed with PBS and stained with 0.4%
crystal violet in 20% methanol for 45 min at RT. Membranes
were washed in ddH2O and stored in PBS at 4 °C. A
minimum of five fields per transwell membrane were imaged
at ×10 magnification using the digital inverted microscope
EVOS Cell Imaging System (Life Technologies, CA, USA).
Total number of migrated cells was manually counted for
each imaged field, the mean was calculated, and normalised
to total protein content by SRB assay. Invasion assays were
performed as above but with additional coating of inner
transwell surfaces with 5 µg Matrigel.
Biotinylated miR/AGO2 pulldown for miR target
identification
Cells seeded in 2 × 10 cm dishes per condition were trans-
fected with 200 pmol biotinylated miR mimic (Exiqon) per
plate for 24 h prior to harvesting, pooling and lysis in 500 µl
per pellet of ice-cold hypotonic lysis buffer (10 mM KCl,
1.5 mM MgCl2, 10 mM Tris-HCl pH7.5, 5 mM DTT, 0.5%
NP40, 60 U/ml SUPERaseIn (Ambion), 5 µl/ml protease
inhibitor cocktail). Lysates were passed through needles
(2 × 23 G, 2 × 27 G) to ensure efficient lysis. Lysates were
cleared by centrifugation at 5000×g for 5 min at 4 °C. 50 µl
of cleared lysate was retained for input RNA extraction.
10 µg AGO2 antibody (Abcam ab57113) diluted in 200 µl
hypotonic lysis buffer was conjugated to 50 µl Dynabeads
Protein G (Invitrogen) per condition by incubation at room
temperature for 20 min with rotation. AGO2-conjugated
beads were washed 3× in hypotonic lysis buffer prior to
incubation with lysate (500 µl) at room temperature for
30 min with rotation. Beads were then washed 3× with
hypotonic lysis buffer and eluted in 50 µl elution buffer
(Dynabeads Protein G IP kit, Invitrogen). NaCl was added
to eluted immunoprecipitated AGO2 complex to a final
concentration of 1M. Reconstituted MyOne C1 streptavidin
beads (LifeTech) were washed 2× in 0.1M NaOH, 0.05M
NaCl, 1× in 0.1 M NaCl and 1× in hypotonic lysis buffer
and blocked with 1 µg/µl BSA and 1 µg/µl yeast tRNA in
hypotonic lysis buffer for 3 h at 4 °C with rotation. Blocked
beads were washed 3× with hypotonic lysis buffer prior to
incubation with immunoprecipitated AGO2 complex for
16 h at 4 °C. Beads were washed 3× with hypotonic lysis
buffer and RNA extracted from both streptavidin beads and
input lysates using 300 µl Trizol LS according to the man-
ufacturer’s protocol. Isolated RNA was reverse transcribed
and qPCR performed as described. RNase-free conditions
were maintained throughout.
AGO-PAR-CLIP-seq
AGO-PAR-CLIP-seq data represented is extracted from
prior published data [31]. Methods are as previously pub-
lished [31].
Patient-derived xenograft (PDX) development CP50
The development of CP50 PDX has been described recently
(Welti et al; submitted to Clinical Cancer Research).
Briefly, a tissue biopsy from a patient with CRPC who had
progressed through all standard of care treatments (doc-
etaxel, cabazitaxel, enzalutamide and abiraterone) was
implanted into 2 NOD scid gamma (NSG) (JAX Mice) male
mice. Next generation sequencing of the parental lymph
node biopsy and generated CP50 PDX demonstrated com-
parable copy number analysis, with chromosome 8 gain and
androgen receptor amplification (Welti et al; submitted to
Clinical Cancer Research). To develop a castrate line,
CP50 PDX was castrated when tumours reached 300 to
400 mm3, and passaged again at a size of 1200 mm3 into
castrate mice, this process was repeated for ongoing main-
tenance. The effect of enzalutamide on castrate CP50 PDX
miR levels was determined at two time points. For both
experiments, animals were treated daily by intraperitoneal
injection with enzalutamide (10 mg/kg) or vehicle (Keptose
HPB) when implanted tumours reached a size of 300 to
400 mm3. Six (n= 3 enzalutamide and n= 3 vehicle) were
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treated for 10 days (short term) and 12 (n= 6 enzalutamide
and n= 6 vehicle) were treated until tumours reached a size
1200 mm3 (long term: 22–48 days).
Statistical analyses
Normally distributed continuous variables were assessed by
Student’s t-test. P ≤ 0.05 was interpreted to denote statistical
significance. Data from miR inhibitor library screening were
analysed using the B score method [53]. The simplest and
most widely used statistical scoring method in high-content
screening is the Z score, however, B score was used here as
it additionally adjusts for positional effects within each 96-
well plate. The expression of mRNA and miRNA in PC
samples was analysed from publically available data sets
GSE34932 and TCGA (mRNA and miRNA-seq). TCGA
data (processed, and Log2 transformed) was accessed from
https://tcga-data.nci.nih.gov/docs/publications/prad_2015/.
IBM-SPSS statistics software was used for analysis of
relationships between miR levels and target gene mRNA
levels, and with clinical attributes. CRPC (n= 122) tran-
scriptome data from SU2C-PCF [32] was re-analysed.
Paired-end transcriptome sequencing reads were aligned to
the human reference genome (GRCh37/hg19) using a RNA-
seq spliced read mapper Tophat2 [54] (Tophat2.0.7), with
default settings. Gene expression, fragments per kilobase of
transcript per million mapped reads (FPKM), was calculated
using Cufflinks [55]. AR activity score is an accumulation
measurement of AR pathway activity based on 43 genes
whose expression level is regulated by AR in PC cell lines
[56] and metastatic PC [57].
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